Equities Analysts Offer Predictions for TEVA FY2024 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research raised their FY2024 earnings per share estimates for Teva Pharmaceutical Industries in a report released on Monday, November 4th. Zacks Research analyst R. Department now anticipates that the company will earn $2.30 per share for the year, up from their prior estimate of $2.29. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.34 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2024 earnings at $0.67 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.77 EPS.

TEVA has been the topic of a number of other research reports. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Barclays increased their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $17.10 on Thursday. The company has a market cap of $19.37 billion, a P/E ratio of -20.11, a P/E/G ratio of 1.25 and a beta of 0.87. The company has a fifty day simple moving average of $17.94 and a 200 day simple moving average of $17.10. Teva Pharmaceutical Industries has a 1 year low of $8.55 and a 1 year high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.04. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.08 billion. Teva Pharmaceutical Industries had a positive return on equity of 41.43% and a negative net margin of 5.73%.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently made changes to their positions in the company. Maple Rock Capital Partners Inc. lifted its stake in Teva Pharmaceutical Industries by 68.3% in the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after buying an additional 1,770,000 shares during the period. National Pension Service increased its stake in Teva Pharmaceutical Industries by 107.3% in the third quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after purchasing an additional 1,640,940 shares in the last quarter. Iron Triangle Partners LP boosted its position in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after purchasing an additional 1,469,864 shares in the last quarter. Driehaus Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $23,115,000. Finally, Davidson Kempner Capital Management LP grew its stake in Teva Pharmaceutical Industries by 152.5% in the second quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock valued at $28,689,000 after acquiring an additional 1,066,150 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.